> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pragmatica-Lung Study Launches
- URL: https://www.fdaweb.com/pragmatica-lung-study-launches/
- Published: 2023-04-12T12:00:00.000Z
- Updated: 2026-09-14T18:25:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154197

The National Cancer Institute (NCI) says it has helped to launch a Phase 3 trial of a two-drug combination to treat patients with advanced non-small cell lung cancer (NCSLC). An NCI [announcement](https://www.cancer.gov/news-events/press-releases/2023/pragmatica-lung-study-begins-enrollment?cid=eb%5Fgovdel&ref=fdaweb.com) says the Pragmatica-Lung Study is part of a broader effort by FDA and the National Institutes of Health to modernize clinical trials.

“Pragmatic clinical trials have fewer and simpler eligibility criteria than conventional trials,” the notice says, “while still ensuring the safety of patients. The hope is that this type of simplified trial can be less burdensome to patients and investigators, accrue study participants faster, be more representative of the real-world patient population, and serve as a model for future clinical trials.”

The trial will evaluate whether a combination of Lilly’s Cyramza (ramucirumab) and Merck’s Keytruda (pembrolizumab) improves overall survival over standard treatment in people with advanced NSCLC whose disease has progressed after previous treatment with immunotherapy and chemotherapy. It will enroll up to 700 participants around the U.S.